echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovative mTOR inhibitor approved by the FDA

    Innovative mTOR inhibitor approved by the FDA

    • Last Update: 2022-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 23, 2021, Aadi Bioscience announced that the US FDA has approved the marketing of the innovative mTOR inhibitor Fyarro (ABI-009) for the treatment of locally advanced unresectable/metastatic malignant perivascular epithelioid cell tumors (PEComa) by intravenous injection.


    This approval is based on positive data obtained from the drug in a phase 2 clinical trial


    mTOR is a type of serine/threonine kinase.


    Sirolimus, also known as rapamycin, is a commonly used specific mTOR inhibitor


    PEComa is an ultra-rare subtype of soft tissue sarcoma driven by mTOR activation.


    Reference materials:

    [1] Aadi Bioscience Announces FDA Approval of its First Product Fyarro™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa).


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.